Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy

Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy

Objective: Rifaximin has been approved for use as a first-line therapy for secondary prophylaxis of hepatic encephalopathy (HE). This article is to update existing evidence on efficacy and safety of rifaximin treatment and prevention for HE.Methods: We systematically searched multiple databases unti...

Full description

Bibliographic Details
Main Authors: Xianghui Han, Zhanyang Luo, Wenyi Wang, Peiyong Zheng, Tian Li, Zubing Mei, Jianyi Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-10-01
Series:Frontiers in Pharmacology
Subjects:
rifaximin
hepatic encephalopathy
efficacy
safety
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.696065/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.696065/full

Similar Items